Publication: 4010

Publication: 4010

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).

PubMed

DOI

Google Scholar

Citation:: ESMO Open vol 10 (12) 105848

Year:: 2025
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Alliance-data-source,-internal-user
Status:: Presented/Published
Citation Status:: epub-ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 15

Parents:: 3425
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Bayer, Bristol-Myers-Squibb, Sanofi
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233253, UG1CA233290, UG1CA233327, UG1CA233373, U10CA189859, U10CA180888 (SWOG)

Corr. Author:
Authors:: L Dercle S Geyer A B Nixon F Innocenti Q Shi S B Jacobson L Luk A Liu H Yang Y Wen B Zhao T Eche F-Z Mokrane M Yang J Meyerhardt E M O'Reilly A P Venook A B El-Khoueiry L H Schwartz G K Abou-Alfa

Networks:: CA011, CA824, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-UT003

Study: Alliance-A151917
Multiple Studies, or Legacy Studies in Alliance Study:: CALGB-80802
Phases:: N/A, 3

Keywords: